Ryan Jacobs, MD; Director of Lymphoma; Associate Professor of Medicine

Director, Division of Lymphoma Therapy & Research, Dept of Hematologic Oncology, Cellular Therapy & Blood Disorders Levine Cancer Institute/Atrium Health, Charlotte, NC, Associate Professor of Internal Medicine, Wake Forest University School of Medicine
Dr. Jacobs joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015, eventually progressing to the rank of associate professor of internal medicine at Wake Forest University School of Medicine. At LCI he has served as a CLL and lymphoma specialist, is a principle investigator on numerous clinical trials. and serves as the Director of the Lymphoma Division. He was promoted to associate professor of internal medicine through the Wake Forest University School of Medicine in 2024. Dr. Jacobs has both a clinical and research focus in patients with lymphoma and Chronic Lymphocytic Leukemia (CLL). In his role as a principal investigator, he oversees the clinical trials conducted at Levine Cancer Institute that involve the treatment of patients with CLL as well as numerous trials in other types of lymphoma. As the CLL expert for the LCI/Atrium Health system, Dr. Jacobs is responsible for creating and overseeing the patient care pathways involving the treatment of CLL patients in the Atrium Health/LCI network that spans North Carolina, South Carolina, and Georgia. In addition to clinical trials, Dr. Jacobs also has a research interest in real world outcomes of patients with lymphoma and CLL on novel therapies and has contributed to this field of research by utilizing the large LCI network and evaluating patients across LCI imprint treated in a variety of clinical settings. He has published many first author manuscripts and has presented at numerous national and international meetings. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbvieDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenmabDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SecuraBioDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BeOneDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JannsenDate added:04/23/2025Date updated:04/23/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ADC TherapeuticsDate added:04/23/2025Date updated:04/23/2025